Obinutuzumab Alone to Successfully and Rapidly Treat Refractory Minimal Change Disease in a Patient with ADPKD (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0727; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "We analyzed, (1) obinutuzumab is much stronger and faster and deeper in sustaining B-cell depletion than rituximab. (2) obinutuzumab was used at the very early stage of MCD onset."
Clinical • Autosomal Dominant Polycystic Kidney Disease • Glomerulonephritis • Infectious Disease • Nephrology • Pneumonia • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases
|